Chief Medical Officer Chad Oh named for Aeon Biopharma

Newport Beach-based clinical-stage drugmaker Aeon Biopharma Inc. this month tapped Chad Oh as chief medical officer.

Oh was most recently vice president of clinical development at the Weinberg Group, a regulatory and compliance services firm. He previously held positions in clinical development at Revance Therapeutics and Glenmark Pharmaceuticals.

He brings “extensive clinical knowledge and experience that provides us great confidence in his ability to lead ABP-450 through all phases of development and the implementation of a successful regulatory strategy,” Chief Executive Marc Forth said in a statement.

Aeon is developing a botulinum toxin called ABP-450—the same toxin used in Newport Beach-based Evolus’ wrinkle-smoothening aesthetic product Jeuveau—for therapeutic treatments. In April, Aeon dosed its first patient in a Phase 2 study for cervical dystonia, a movement disorder caused by the involuntary contraction of neck muscles.

The company raised a $25 million investment from South Korean partner Daewoong Pharmaceutical last September.